Please use this identifier to cite or link to this item:
https://doi.org/10.1186/s13045-019-0814-6
DC Field | Value | |
---|---|---|
dc.title | EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications | |
dc.contributor.author | Li, B. | |
dc.contributor.author | Chng, W.-J. | |
dc.date.accessioned | 2021-12-16T07:46:04Z | |
dc.date.available | 2021-12-16T07:46:04Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Li, B., Chng, W.-J. (2019). EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications. Journal of Hematology and Oncology 12 (1) : 118. ScholarBank@NUS Repository. https://doi.org/10.1186/s13045-019-0814-6 | |
dc.identifier.issn | 17568722 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/210718 | |
dc.description.abstract | EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which along with other PRC2 components mediates gene expression suppression via the methylation of Histone H3 at lysine 27. Recent studies have revealed a dichotomous role of EZH2 in physiology and in the pathogenesis of cancer. While it plays an essential role in the development of the lymphoid system, its deregulation, whether due to genetic or non-genetic causes, promotes B cell-and T cell-related lymphoma or leukemia. These findings triggered a boom in the development of therapeutic EZH2 inhibitors in recent years. Here, we discuss physiologic and pathogenic function of EZH2 in lymphoid context, various internal causes of EZH2 aberrance and how EZH2 modulates lymphomagenesis through epigenetic silencing, post-translational modifications (PTMs), orchestrating with surrounding tumor micro-environment and associating with RNA or viral partners. We also summarize different strategies to directly inhibit PRC2-EZH2 or to intervene EZH2 upstream signaling. © 2019 The Author(s). | |
dc.publisher | BioMed Central Ltd. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scopus OA2019 | |
dc.subject | B cell | |
dc.subject | EBV | |
dc.subject | EZH2 | |
dc.subject | EZH2 inhibitor | |
dc.subject | Lymphoid malignancies | |
dc.subject | Lymphoma | |
dc.subject | T cell | |
dc.type | Review | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.1186/s13045-019-0814-6 | |
dc.description.sourcetitle | Journal of Hematology and Oncology | |
dc.description.volume | 12 | |
dc.description.issue | 1 | |
dc.description.page | 118 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1186_s13045-019-0814-6.pdf | 777.85 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License